

Other focused conferences during WorldPharma2010

- 1: Clinical pharmacology in emerging and developing countries
- 2: Transmembrane transport: perspectives for disease and drug discovery
- 3: Ion channels in analgesia and anaesthesia
- 4: Pharmacoepidemiology, current controversies and opportunities
- 5: Translational science in the metabolic syndrome: basic and clinical pharmacology
- 6: The heart gone wrong; stabilization of cardiac function
- 7: Simulation and data modelling in drug development. Better drugs faster?
- 8: Developments in the treatment of sexual dysfunction and diseases of the lower urinary tract
- 10: Drugs for half the world: paediatric clinical pharmacology
- 11: G protein-coupled 7TM receptors:
from molecular to physiological function
- 12: Ion channelopathies:
new windows on complex disease and therapy
- 13: Maximising benefits and minimizing harms from drugs
- 14: Addiction and doping:
neurobiological and clinical basis of emerging treatments
- 15: Endothelium in health and disease
- 16: Natural products: past and future?
- 17: New approaches and targets in psychiatry
- 18: Nuclear receptor targets for treatment of diseases

Danish Society for 
Pharmacology



BCPT
Basic & Clinical Pharmacology & Toxicology



Printed in Denmark

Please find further details on www.WorldPharma2010.org



WorldPharma2010

16th World Congress on Basic and Clinical Pharmacology.
July 17-23, 2010, Copenhagen, Denmark

WorldPharma2010 will include a
3-day focused conference on

**Inflammation and
immunopharmacology:
new tools for old diseases**

19-21 July 2010

Abstract deadline 15 January 2010
Early bird registration deadline 15 March 2010

Invitation

July 17-23 2010 is the time for a major event for pharmacology, the science of how drugs affect the living organism. Basic and clinical pharmacology, kept separate for too long, have come together again to encompass the whole process of drug development from molecular biology to clinical practice. This remarriage is to be celebrated in Copenhagen; the world's basic and clinical pharmacologists and all those dealing with the development and use of drugs will meet to discuss how we can work together to meet the need for safe and effective medicines at affordable prices.

WorldPharma2010 is organised by the Danish Society for Pharmacology jointly with the British Pharmacological Society under the auspices of the International Union of Basic and Clinical Pharmacology, IUPHAR.

In the scientific programme, there will be plenary lectures, poster sessions, sponsored symposia, workshops, satellite meetings and focused conferences. Each of the 18 focused conferences contains 4 or 5 half-day sessions all belonging to the same theme. Overleaf is the detailed programme for the focused conference entitled:

"Inflammation and immunopharmacology: new tools for old diseases"

The titles of the other focused conferences are listed on the back of the folder.

In each session there will be free communications as well. We promise you a scientifically excellent programme as well as the opportunity to savour the atmosphere of Copenhagen.



Kim Brøsen
President



Michael Mulvany
Secretary General

Congress secretariat



ICS A/S Copenhagen

Strandvejen 169-171 - P.O. Box 41 - DK-2900 Hellerup, Copenhagen - Denmark
Email: WorldPharma2010@ics.dk - Phone: +45 7023 7823 - Fax: +45 7023 7888
www.worldpharma2010.org

Inflammation and immunopharmacology: new tools for old diseases

Focused conference leaders: Ian Adcock, Frans P. Nijkamp & Salvador Moncada

Focused conference coordinator: Eeva Moilanen

Session 1 Steroids and beyond: novel treatments for asthma and allergy

Chairpersons:
I. Adcock & H. Inoue

- Improving current steroids
I. Adcock, UK
- The mast cell as a target for new anti-asthma / allergy drugs (Mast cells and mast cell-derived factors in the regulation of allergic sensitization)
C. Taube, Germany
- Inhibition of T-cells and T-cell mediators. (Effector and regulatory T cells in asthma)
C. A. Akdis, Switzerland
- Suppressor of cytokine signaling in asthma
H. Inoue, Japan

Session 2 Biologicals in inflammatory diseases - successes, promises and problems

Chairpersons:
M. Feldmann & T. W. J. Huizinga

- TNF-alpha antagonists – translating molecular insights in autoimmunity into effective therapy
M. Feldmann, UK
- Novel biologicals in the treatment of rheumatoid arthritis – abatacept, rituximab, IL-6 antagonists and beyond
T. W. J. Huizinga, Netherlands
- Immunomodulatory drugs in multiple sclerosis – from interferon alpha to specific monoclonal antibodies
R. Martin, Germany
- Immunogenicity and other problems in the use of biologicals
M. G. Tovey, France

Session 3 iNOS - nitric oxide pathway in inflammation and as a target of anti-inflammatory treatment

Chairpersons:
E. Moilanen & S. Moncada

- NO as a factor in inflammation
E. Moilanen, Finland
- Exhaled NO in the diagnosis and therapy monitoring of inflammatory airway disease
K. Alving, Sweden
- Peroxynitrite and NO / iNOS derived radicals in inflammation OR Nitrosative stress in inflammation
D. A. Wink, USA
- iNOS inhibitors in inflammatory diseases: lessons from animal and human studies
R. G. Knowles, UK
- NO, mitochondrial function and tissue injury in inflammation and septic shock
S. Moncada, UK

Session 4 NSAIDs and COX-2 inhibitors. Current strategies and future directions

Chairpersons:
J. A. Mitchell & P. Jakobsson

- Pharmacology of COX-1 and COX-2: is there still a place for COX-2 selective NSAIDs?
J. A. Mitchell, UK
- Anti-inflammatory benefits and cardiovascular toxicity of NSAIDs and COX-2 inhibitors
P. Patrignani, Italy
- Endocannabinoids and beyond. Paracetamol, NSAIDs and novel mechanisms to treat inflammatory pain
P. Zygmunt, Sweden
- COX-2 and cancer
A. Ristimäki, Finland
- Inhibitors of PGE synthases
P. Jakobsson, Sweden

Session 5 Novel anti-inflammatory targets and mechanism

Chairpersons:
F. P. Nijkamp & J. E. Blalock

- Dendritic cells as target for immunomodulation
G. G. Brusselle, Belgium
- CXC chemokines and antagonists in chronic inflammation
G. Folkerts, Netherlands
- Neuro-immune interactions in health and disease
E. Blalock, USA
- Toll-like receptors as new targets for immune disorders
L. A. J. O'Neill, Ireland